MyLymphomaTeam

While marginal zone lymphoma (MZL) often responds well to initial treatment, it tends to relapse over time. The recurrence rates vary by MZL subtype. MALT lymphoma, which is the most common type, has better outcomes with approximately 90% of patients surviving at least 5 years after treatment. Splenic marginal zone lymphoma Show Full Answer

While marginal zone lymphoma (MZL) often responds well to initial treatment, it tends to relapse over time. The recurrence rates vary by MZL subtype. MALT lymphoma, which is the most common type, has better outcomes with approximately 90% of patients surviving at least 5 years after treatment. Splenic marginal zone lymphoma (SMZL) and nodal marginal zone lymphoma (NMZL) have lower survival rates, ranging from 50-70%. For SMZL specifically, while many people respond well to treatments like rituximab and chemotherapy, the lymphoma tends to relapse over time. New treatments like BTK inhibitors are showing promise in helping patients with relapsed/refractory SMZL.

 AI-generated responses are not a substitute for medical advice. These services are not intended to diagnose, treat, or cure any condition or disease. Always ask your doctor about specific health concerns.

Marginal Zone Lymphoma: An Overview

Splenic Marginal Zone Lymphoma: Prognosis, Symptoms, and More